- Home
- ALNY
as 01-21-2025 4:00pm EST
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia. It also has several clinical programs across various therapeutic areas: genetic medicines; cardio-metabolic diseases; hepatic infectious diseases, and CNS/ocular diseases. Upfront fees from research partnerships have boosted Alnylam's cash levels, and the company stands to see additional milestones and royalties from drugs commercialized under collaboration partnerships.
| Founded: | 2002 | Country: | United States |
| Employees: | N/A | City: | CAMBRIDGE |
| Market Cap: | 33.2B | IPO Year: | 2004 |
| Target Price: | $299.09 | AVG Volume (30 days): | 643.5K |
| Analyst Decision: | Buy | Number of Analysts: | 24 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.62 | EPS Growth: | N/A |
| 52 Week Low/High: | $141.98 - $304.39 | Next Earning Date: | 02-13-2025 |
| Revenue: | $2,094,795,000 | Revenue Growth: | 21.54% |
| Revenue Growth (this year): | 24.87% | Revenue Growth (next year): | 18.53% |
Stock Insider Trading Activity of Alnylam Pharmaceuticals Inc. (ALNY)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Garg Pushkal | ALNY | CMO & EVP Dev & Med Affairs | Dec 12 '24 | Sell | $251.62 | 1,752 | $439,759.94 | 15,705 | |
| Fitzgerald Kevin Joseph | ALNY | CSO & EVP, Head of Research | Nov 25 '24 | Sell | $251.34 | 3,000 | $754,946.54 | 15,640 | |
| Greenstreet Yvonne | ALNY | Chief Executive Officer | Nov 25 '24 | Sell | $250.35 | 5,219 | $1,309,852.75 | 83,244 | |
| Garg Pushkal | ALNY | CMO & EVP Dev & Med Affairs | Nov 25 '24 | Sell | $250.35 | 1,682 | $422,144.31 | 15,705 | |
| Tanguler Tolga | ALNY | EVP, Chief Commercial Officer | Nov 25 '24 | Sell | $250.35 | 1,469 | $368,685.86 | 14,634 | |
| Poulton Jeffrey V. | ALNY | EVP, Chief Financial Officer | Nov 25 '24 | Sell | $250.35 | 1,682 | $422,144.31 | 30,644 |
Latest Alnylam Pharmaceuticals Inc. News
ALNY Breaking Stock News: Dive into ALNY Ticker-Specific Updates for Smart Investing
Zacks
19 hours ago
New Strong Buy Stocks for January 21st
Zacks
9 days ago
ALNY Announces Preliminary 2024 Results, 2025 View & Pipeline Goals
Business Wire
9 days ago
Alnylam Announces Preliminary* Fourth Quarter and Full Year 2024 Global Net Product Revenues and Provides 2025 Combined Net Product Revenue Guidance and Pipeline Goals
Business Wire
16 days ago
Alnylam to Webcast Presentation at 43rd Annual J.P. Morgan Healthcare Conference
Simply Wall St.
a month ago
Exploring High Growth Tech Stocks in the US December 2024
Zacks
a month ago
Is Alnylam Pharmaceuticals (ALNY) Stock Outpacing Its Medical Peers This Year?
Insider Monkey
a month ago
Is Alnylam Pharmaceuticals, Inc. (ALNY) the Best Performing Biotech Stock in 2024?
Zacks
a month ago
The Zacks Analyst Blog Highlights Sarepta Therapeutics, ADMA Biologics, Exelixis and Alnylam
Compare ALNY vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "ALNY Alnylam Pharmaceuticals Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.